Enliven® Services

Administering ENBREL

Enlarge text size. Print this page. Email
Administering ENBREL

Get answers and assistance

With the right information and the proper training, administering ENBREL can be simple.

 
Administering FAQs
What are the recommended injection sites for administering ENBREL?

Sometimes the skin around the injection site becomes red and itchy. Is this normal?

After mixing the liquid and the powder, the solution appeared cloudy. Does this matter?

What should I do with my needles after I inject?

What should I do with my needle disposal container once it's full?

 

What are the recommended injection sites for administering ENBREL?

Choose an injection site on the front of the middle thighs or on the abdomen, except for the two-inch area right around the navel. These areas usually have enough tissue for the injection and are easy to reach. If a parent or caregiver is performing the injection, the outer area of the upper arms is another option.

Rotate the site for each injection. DO NOT inject into areas where the skin is tender, bruised, red, or hard. Avoid areas with scars or stretch marks.

If you have psoriasis, you should try not to inject directly into any raised, thick, red, or scaly skin patches or lesions.

 
Return to Top

 

Sometimes the skin around the injection site becomes red and itchy. Is this normal?

In medical studies, some patients experienced mild to moderate injection site reactions, usually within the first month. Most reactions resolved without discontinuation of ENBREL. If you have any concerns, talk to your doctor.

 

After mixing the liquid and the powder, the solution appeared cloudy. Does this matter?

Before mixing, the powder should be white. After you add the liquid (diluent), the powder usually dissolves in about 10 minutes. The mixed solution should be clear and colorless. (A small amount of foam or bubbles may be present; this is normal.) Do not inject the solution if it is discolored, or contains lumps, flakes, or particles. If all the powder in the ENBREL vial is not dissolved or there are particles present after 10 minutes, call 1-888-4ENBREL (1-888-436-2735) for assistance.

 
Return to Top

 

What should I do with my needles after I inject?

Follow these safety guidelines when disposing of used needles:
  • Immediately after each injection, you should discard the used needles, syringes, or autoinjectors in a puncture-resistant container specifically designed for their disposal. These are often called SHARPS containers because they can hold sharp items securely.
  • NEVER recap or reuse a needle, syringe, or autoinjector.
  • Keep the SHARPS container out of the reach of children.

 

What should I do with my needle disposal container once it's full?

Once you've filled your SHARPS container with used needles, syringes, or autoinjectors, you need to dispose of it as instructed by your health care professional. For public safety reasons, containers generally require special disposal. State and local laws for disposing of needles vary considerably from town to town. For information in your area, call 1-888-4ENBREL (1-888-436-2735).

Important: Do not recycle the SHARPS container. Never put your SHARPS container in the trash with other plastic recyclables (unless your local laws permit this). And never empty the contents of your SHARPS container in order to reuse it.

 

Ongoing Support

All FAQs
Insurance
Administering ENBREL
  Dosing and Scheduling
  Injection Instructions
  Travel and Storage
  Needle/Syringe Disposal
Resources and Forms

Medication Guide for ENBREL
Please read the Medication Guide for ENBREL and discuss with your doctor.
Questions? Call toll-free 1-888-4ENBREL (1-888-436-2735).
Enliven Services representatives are available to assist you 8 am to 8 pm, Eastern time, Monday through Friday,
and Enliven Services registered nurses are available 8 am to 11 pm, Eastern time, 7 days a week.
Para ayuda en español oprima el número nueve.
Visit www.enbrel.com

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about ENBREL?

ENBREL is a medicine that affects your immune system. ENBREL can lower the ability of your immune system to fight infections. Serious infections have happened in patients taking ENBREL. These infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some patients have died from these infections. Your doctor should test you for TB before you take ENBREL and monitor you closely for TB before, during, and after ENBREL treatment, even if you have tested negative for TB.

There have been some cases of unusual cancers reported in children and teenage patients who started using TNF blockers before 18 years of age. Also, for children, teenagers, and adults taking TNF blockers, including ENBREL, the chances of getting lymphoma or other cancers may increase. Patients with RA and psoriasis may be more likely to get lymphoma.

Before starting ENBREL, tell your doctor if you:
  • Have any existing medical conditions
  • Are taking any medicines, including herbals
  • Think you have, are being treated for, have signs of, or are prone to infection. You should not start taking ENBREL if you have any kind of infection, unless your doctor says it is okay
  • Have any open cuts or sores
  • Have diabetes or an immune system problem
  • Have TB or have been in close contact with someone who has had TB
  • Were born in, lived in, or traveled to countries where there is more risk for getting TB. Ask your doctor if you are not sure
  • Live or have lived in certain parts of the country (such as, the Ohio and Mississippi River valleys, or the Southwest) where there is a greater risk for certain kinds of fungal infections, such as histoplasmosis. These infections may develop or become more severe if you take ENBREL. If you don't know if histoplasmosis or other fungal infections are common in the areas where you live or have lived, ask your doctor.
  • Have or have had hepatitis B
  • Have heart failure
  • Develop symptoms such as persistent fever, bruising, bleeding, or paleness while taking ENBREL
  • Use the medicine Kineret® (anakinra), Orencia® (abatacept), or Cytoxan® (cyclophosphamide)
  • Have or develop a serious nervous disorder, seizures, any numbness or tingling, or a disease that affects your nervous system such as multiple sclerosis
  • Are scheduled to have surgery
  • Have recently received or are scheduled for any vaccines. All vaccines should be brought up-to-date before starting ENBREL. Patients taking ENBREL should not receive live vaccines.
  • Are allergic to rubber or latex
  • Are pregnant, planning to become pregnant, or breastfeeding
  • Have been around someone with chicken pox

What are the possible side effects of ENBREL?

ENBREL can cause serious side effects including: Infections, including serious infections like TB; hepatitis B can become active if you already have had it; nervous system problems, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes; blood problems (some fatal); new or worsening heart failure; new or worsening psoriasis; allergic reactions; autoimmune reactions, including a lupus-like syndrome and autoimmune hepatitis.

Common side effects include: Injection site reactions, upper respiratory infections (sinus infections), and headache.

In a medical study of patients with JIA, infection, headache, abdominal pain, vomiting, and nausea occurred more frequently than in adults. The kinds of infections reported were generally mild and similar to those usually seen in children. Other serious adverse reactions were reported, including serious infection and depression/personality disorder.

These are not all the side effects with ENBREL. Tell your doctor about any side effect that bothers you or does not go away.

If you have any questions about this information, be sure to discuss them with your doctor. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see Prescribing Information and Medication Guide.

INDICATIONS

Moderate to Severe Rheumatoid Arthritis (RA)
ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with moderate to severe rheumatoid arthritis. ENBREL can be taken with methotrexate or used alone.
  • In medical studies, ENBREL was shown to be effective in about 2 out of 3 adults with RA who used it, and has been shown to begin working in as few as 2 weeks, with most patients receiving benefit within 3 months. In an RA medical study, 55% of patients had no progression of joint damage.
Moderate to Severe Polyarticular Juvenile Idiopathic Arthritis (JIA)
ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in children ages 2 years and older.
  • In a medical study, ENBREL was shown to be effective in about 3 out of 4 children with JIA who used it. For these JIA patients, ENBREL has been shown to begin working in approximately 2 to 4 weeks.
Psoriatic Arthritis
ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.
  • In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients who used it. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.
Ankylosing Spondylitis (AS)
ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.
  • In a medical study, ENBREL was shown to be effective in about 3 out of 5 adults with AS who used it. Clinical responses were seen at 2 weeks in 46% of patients, with 59% of patients receiving benefit within 8 weeks.
Moderate to Severe Plaque Psoriasis
ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
  • In medical studies, nearly half of patients saw a significant improvement in their plaque psoriasis within 3 months of using ENBREL. Overall, 3 out of 4 patients saw improvement. ENBREL can work fast; many patients saw improvement within 2 months. ENBREL has been shown to be effective through 12 months of therapy.

About Amgen and Wyeth | Privacy Policy | Terms of Use | Site Index
Important Safety Information | Prescribing Information | Medication Guide | Patient Instructions for Use

Amgen®Wyeth®

This site is intended for U.S. audiences only.
Manufactured by Immunex Corporation, Thousand Oaks, CA 91320. Marketed by Amgen and Wyeth Pharmaceuticals.
©2009 Amgen, Thousand Oaks, CA 91320 and Wyeth Pharmaceuticals Inc., Collegeville, PA 19426